Lekha Mikkilineni
Overview
Explore the profile of Lekha Mikkilineni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
976
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, et al.
Blood Adv
. 2025 Mar;
PMID: 40088469
No abstract available.
2.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500453.
PMID: 40053892
No abstract available.
3.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401730.
PMID: 39965175
Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety,...
4.
Reddy S, Hosoya H, Mikkilineni L
Cancer Metastasis Rev
. 2024 Dec;
44(1):14.
PMID: 39625587
Chimeric antigen receptor (CAR) T-cell therapy represents a transformative advancement in treating relapsed or refractory multiple myeloma (MM) in both early- and late-line settings. MM, a plasma cell malignancy, traditionally...
5.
Bharadwaj S, Lowsky R, Mikkilineni L, Smith M, Weng W
J Cancer Educ
. 2024 Nov;
PMID: 39604772
The field of allogeneic blood and marrow transplantation-cellular therapy (BMT-CT) has evolved through incremental advances. Engineered donor grafts, gene editing and chimeric antigen receptor T-cells are all standard clinical practice....
6.
Galarza Fortuna G, Banerjee R, Savid-Frontera C, Song J, Moran-Segura C, Nguyen J, et al.
Blood Cancer J
. 2024 Oct;
14(1):180.
PMID: 39414769
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and...
7.
Sidana S, Patel K, Peres L, Bansal R, Kocoglu M, Shune L, et al.
Blood
. 2024 Oct;
145(1):85-97.
PMID: 39365257
Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for...
8.
Shahid Z, Jain T, Dioverti V, Pennisi M, Mikkilineni L, Thiruvengadam S, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):955-969.
PMID: 39084261
Chimeric antigen receptor (CAR) T-cell therapy is rapidly advancing, offering promising treatments for patients with hematological malignancy. However, associated infectious complications remain a significant concern because of their contribution to...
9.
Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, et al.
Blood
. 2024 Jul;
144(16):1689-1698.
PMID: 38968138
Although chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, many patients relapse and therefore strategies to improve antitumor immunity are needed. We previously designed...
10.
Bharadwaj S, Lau E, Hamilton M, Goyal A, Srinagesh H, Jensen A, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 38955420
Background: Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens...